Table of Content

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Antidiabetic Drugs Market, by Region

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of diabetes and increasing obesity among people
5.1.1.2. Growing awareness among patients and healthcare professionals regarding the importance of diabetes management
5.1.1.3. Initiatives and programs supporting diabetes awareness & treatment
5.1.2. Restraints
5.1.2.1. Adverse effects associated with antidiabetic drugs
5.1.3. Opportunities
5.1.3.1. Ongoing research and development for new antidiabetic drugs
5.1.3.2. Governments and private companies collaborations to supply inexpensive drugs
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements for the approval of antidiabetic drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization

6. Antidiabetic Drugs Market, by Type
6.1. Introduction
6.2. Alpha-Glucosidase Inhibitors
6.3. Biguanides
6.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
6.5. GLP-1 (Glucagon-like Peptide) Agonists
6.6. Insulin
6.7.1. Intermediate-Acting Insulin
6.7.2. Long-Acting Analog
6.7.3. Premixed Insulin
6.7.4. Rapid-Acting Analog
6.7.5. Short-Acting Analog
6.7. Meglitinides
6.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
6.9. Sulphonylureas
6.10. Thiazolidinedione

7. Antidiabetic Drugs Market, by Disease
7.1. Introduction
7.2. Diabetes Mellitus Type 1
7.3. Diabetes Mellitus Type 2

8. Antidiabetic Drugs Market, by Patient
8.1. Introduction
8.2. Adult
8.3. Geriatric
8.4. Pediatric

9. Americas Antidiabetic Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Antidiabetic Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Antidiabetic Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. Alkem Laboratories Ltd.
13.1.3. Aristo Pharmaceuticals Pvt. Ltd.
13.1.4. Astellas Pharma Inc.
13.1.5. AstraZeneca PLC
13.1.6. Biocon Limited
13.1.7. Boehringer Ingelheim International GmbH
13.1.8. Cadila Pharmaceuticals Limited
13.1.9. Cipla Limited
13.1.10. Dr. Reddy’s Laboratories
13.1.11. Eli Lilly and Company
13.1.12. F. Hoffmann-La Roche Ltd.
13.1.13. GlaxoSmithKline PLC
13.1.14. Glenmark Pharmaceuticals Ltd.
13.1.15. Halozyme Therapeutics, Inc.
13.1.16. Johnson & Johnson Services, Inc.
13.1.17. Mankind Pharma Ltd.
13.1.18. Merck KGaA
13.1.19. Novo Nordisk A/S
13.1.20. Oramed Pharmaceuticals Inc.
13.1.21. Pfizer Inc.
13.1.22. PHC Holdings Corporation
13.1.23. Sanofi S.A.
13.1.24. Takeda Pharmaceutical Company Limited
13.1.25. Teva Pharmaceutical Industries Ltd.
13.1.26. Tonghua Dongbao Pharmaceutical Co., Ltd.
13.2. Key Product Portfolio

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing



List of Figures

FIGURE 1. ANTIDIABETIC DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTIDIABETIC DRUGS MARKET SIZE, 2022 VS 2030
FIGURE 3. ANTIDIABETIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. ANTIDIABETIC DRUGS MARKET DYNAMICS
FIGURE 7. ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 8. ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2022 VS 2030 (%)
FIGURE 10. ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2022 VS 2030 (%)
FIGURE 12. ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 14. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 16. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 22. ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2022

List of Tables

TABLE 1. ANTIDIABETIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2022
TABLE 3. ANTIDIABETIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. ANTIDIABETIC DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ANTIDIABETIC DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ANTIDIABETIC DRUGS MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. ANTIDIABETIC DRUGS MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 12. ANTIDIABETIC DRUGS MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ANTIDIABETIC DRUGS MARKET SIZE, BY LONG-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ANTIDIABETIC DRUGS MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. ANTIDIABETIC DRUGS MARKET SIZE, BY RAPID-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. ANTIDIABETIC DRUGS MARKET SIZE, BY SHORT-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. ANTIDIABETIC DRUGS MARKET SIZE, BY MEGLITINIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. ANTIDIABETIC DRUGS MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. ANTIDIABETIC DRUGS MARKET SIZE, BY SULPHONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. ANTIDIABETIC DRUGS MARKET SIZE, BY THIAZOLIDINEDIONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 22. ANTIDIABETIC DRUGS MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. ANTIDIABETIC DRUGS MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 25. ANTIDIABETIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. ANTIDIABETIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. ANTIDIABETIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 41. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 43. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 44. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 45. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 47. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 48. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 62. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 63. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 65. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 66. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 67. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 69. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 70. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 73. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 74. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 75. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 77. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 78. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 81. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 82. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 85. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 86. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 89. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 90. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 93. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 94. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 97. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 98. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 99. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 101. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 102. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 105. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 106. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 112. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 114. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 115. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 116. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 118. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 119. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 120. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 122. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 123. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 124. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 126. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 127. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 128. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 130. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 131. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 133. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 134. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 135. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 136. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 138. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 139. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 143. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 145. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 146. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 147. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 148. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 150. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 151. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 152. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 153. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 154. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 155. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 156. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 158. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 159. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 172. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 173. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 174. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 175. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 182. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 183. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 184. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 186. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 187. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 196. ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 197. ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 198. ANTIDIABETIC DRUGS MARKET LICENSE & PRICING